Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Novavax statement on EMA Nuvaxovid label update related to allergic reaction

Novavax’ clinical development program reported no severe allergic reactions

CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine

Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.

Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.

Eversana partners with Compai Pharma to expand commercialisation services across APAC

EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners

CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine

CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.

Pfizer submits new drug application to the U.S. FDA for Paxlovid

Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk

Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918

This multicenter, open-label Phase I study is designed to assess the safety and tolerability

Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival in patients

Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects